Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration ( FDA ) for Gimoti™ 505(b)(2) New Drug Application (NDA) April 1 , 2019 Prescription Drug User Fee Act (PDUFA) date maintained Company expects to hold a conference call at a later date instead of its
Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ dose Announced discovery of sex-based pharmacokinetic differences for Gimoti™ Met with FDA regarding NDA women-only filing strategy and post-marketing plans 505(b)(2) NDA submission planned for
SOLANA BEACH, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2016.
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif. , May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Net product sales increased by 94% from Q1 2022 New cumulative prescribers up by 17% from Q4 2022 Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily
Several sales growth indicators increased over Q4, 2021: New Prescribers up 41%; Product delivered to patients up 39%; Net Revenue increased by 16%; Prescriptions written up 22% SOLANA BEACH, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ® New notice of allowance from USPTO to expand Gimoti patent estate SOLANA BEACH, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter
The Company will hold a conference call following submission of Gimoti NDA NDA submission for Gimoti™ on track for second quarter of 2018 Announced discovery of sex-based pharmacokinetic differences for Gimoti Waiver of the PDUFA fee for Gimoti NDA granted by FDA Cash runway extended into April